All In Biotech

Drug Trial Radar · NCT07292441

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

A Multicenter Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

224

Actual

Start

Jan 22, 2026

Primary completion

Sep 22, 2026

Study completion Sep 22, 2026

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight. In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.

Conditions

  • Overweight or Obesity

Interventions

  • GZR18 injectionDrug

    Used as specified in the protocol

  • PlaceboOther

    Administered the same volume as GZR18

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change (%) from baseline in body weightTime frame: from Week 0 (W0) to Week 24 (W24)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Study site 01

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.